TG Therapeutics TGTX shares are trading higher on Thursday after the company announced that the FDA accepted its new drug application for its Umbralisib as a treatment for patients with the previously-treated marginal zone Lymphoma and Follicular Lymphoma.
TG Therapeutics is a biopharmaceutical company. It's engaged in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.
The company is developing two therapies targeting hematologic malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a unique epitope on the CD20 antigen found on mature B-lymphocytes.
TG Therapeutics shares were trading up 6.35% at $20.26 on Thursday at the time of publication. The stock has a 52-week high of $24.76 and a 52-week low of $4.95.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
